Page 301 - Personalised medicine of fluoropyrimidines using DPYD pharmacogenetics Carin Lunenburg

References
1. Henricks LM, Kienhuis E, de Man FM, et al. Treatment algorithm for homozygous or compound heterozygous DPYD variant allele carriers with low dose capecitabine. JCO Precis Oncol. 2017.
2. Deenen MJ, Meulendijks D, Cats A, et al. Upfront Genotyping of DPYD*2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis. J Clin Oncol. 2016;34(3):227-234.
3. Regan JF, Kamitaki N, Legler T, et al. A rapid molecular approach for chromosomal phasing. PloS one. 2015;10(3):e0118270.
4. Buermans HP, Vossen RH, Anvar SY, et al. Flexible and Scalable Full-Length CYP2D6 Long Amplicon PacBio Sequencing. Hum Mutat. 2017;38(3):310-316.
5. van der Straaten T, Swen J, Baak-Pablo R, Guchelaar HJ. Use of plasmid-derived external quality control samples in pharmacogenetic testing. Pharmacogenomics. 2008;9(9):1261-1266.
Supplement
299
11